2017 Preliminary Results · 2020-03-03 · 1 2017 Preliminary Results. Martyn Ratcliffe. Chairman....
Transcript of 2017 Preliminary Results · 2020-03-03 · 1 2017 Preliminary Results. Martyn Ratcliffe. Chairman....
1
2017 Preliminary Results
Martyn RatcliffeChairman
Rebecca ArcherFinance Director
To be read in conjunction with the audited preliminary results announcement released on 28 February 2018
In addition to IFRS measures, alternative performance measures are used in this presentation. Refer to the Notes to the financial statements within the preliminary results announcement for detail and explanation.
2
Group revenue of £40.8m (2016: £36.9m)
Adjusted operating profit of £6.9m (2016: £6.2m)• Adjusted EBITDA of £7.6m (2016: £7.0m)
Statutory PBT of £3.9m (2016: £3.0m)
Adjusted basic EPS increased to 12.8 pence (2016: 11.4 pence)• Basic EPS of 7.7 pence (2016: 6.8 pence)
Cash balance of £19.9m (2016: £26.0m) and Net Funds of £6.0m (2016: £11.3m)• After capital of £13.2m deployed via acquisition of TSG (net capital outflow of £10.4m)• Excludes cash held on behalf of clients for regulatory registration of £0.9m• Cash generated from operations (excluding client registration funds) of £7.8m (2016: £11.6m)
Proposed dividend increase to 4.4 pence per share (2016: 4.2 pence per share)
Financial Summary
3
Group Revenue Breakdown
0
5
10
15
20
25
30
35
40
45
2010 2011 2012 2013 2014 2015 2016 2017
Rev
enue
(£m
)
Non Core: PropertyincomeCore Business:Other revenueCore Business:Services revenue
• Largest customer accounted for approx 10%• 2017 includes only 4 months of TSG revenue (post-acquisition period: £4.9m)• Group revenue benefitted by £0.7m from favourable forex rates compared to 2016
4
Strategic Axes
Market Sector
GeographyServiceService
5
Markets & Services
Med
ical
Com
mer
cial
Food
& B
ever
age
Applied Science
Technology Advisory
Product Development
Regulatory
6
• Business model structured around vertical markets• Five distinct brands under Science Group umbrella brand
Market Sector Revenue Profile
Medical
Commercial
Food & Beverage
Market Sector Overview
• Medical: Very strong performance in PD in 2017 and excellent momentum entering 2018.
• Commercial: Satisfactory performance in Advisory but disappointing in PD due to combination of market and internal execution. PD management change undertaken.
• Food & Beverage: Good performance in Regulatory services. Increasingly integrated sector offering with Science and Advisory services under Leatherhead brand.
Q4 2017 Data
7
Services Revenue Profile
Applied Science & Product
Development
Advisory
Regulatory
OtherServices Developments
• Applied Science : Consolidated Sagentia and Leatherhead science teams into single function.
• Advisory : Consolidated all advisory activities into single organisation with 4 vertical markets: Food & Beverage; Medical; Commercial and Chemicals & Energy
• Regulatory : Significantly expanded service offering and geographical footprint through TSG acquisition. Strong performance in Food & Beverage sector. Increasing coordination of all Regulatory services across Europe
Q4 2017 Data
8
• 83% (2016: 74%) of Core Business revenue is derived from outside UK• 35% of Core Business revenue invoiced in USD (2016: 35%) and 10% in EUR (2016: 11%)• TSG acquisition did not materially change the currency/geographic revenue profile• Increase in revenue from Europe due to large Sagentia contracts
Revenue by Currency/Geography
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2013 2014 2015 2016 2017
OtherGBPEURUSD
Core Business Revenue by Currency Core Business Revenue by Geography
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2013 2014 2015 2016 2017
Rest of WorldUKEuropeNorth America
9
Geographical Presence
TSG acquisition significantly expanded Group international footprint
President of Science Group North America appointed to lead integrated service offeringin strategic market
New European MD and European Operations Director appointed to integrate Regulatoryservices across countries and maximisescale synergies
10
• Adjusted operating profit increased to £6.9m (2016: £6.2m)• Adjusted EBITDA of £7.6m (2016: £7.0m)• Strong operating margin performance maintained despite acquisition integration disruption• FX benefit (£0.6m) partially allocated to organic investment
Adjusted Operating Profit
0%
4%
8%
12%
16%
20%
24%
28%
0
1
2
3
4
5
6
7
8
2010 2011 2012 2013 2014 2015 2016 2017
Adjustedoperating profit
Adjustedoperating profitmargin
Adj
uste
d op
erat
ing
prof
it (£
m)
Adj
uste
d op
erat
ing
prof
it m
argi
n (%
)
11
• Adjusted basic EPS increased to 12.8 pence (2016: 11.4 pence)• Weighted average number of shares decreased by 3% due to 2016 share buy backs• At 31 December 2017, ISC was approx 5% less than at end 2010
Adjusted Earnings per Share
-
2p
4p
6p
8p
10p
12p
14p
0
1
2
3
4
5
6
7
8
2010 2011 2012 2013 2014 2015 2016 2017
Adjustedoperating profit
Adjusted EPS(basic)
Adjusted EPS(diluted)A
djus
ted
EPS
(pen
ce)
Adj
uste
d op
erat
ing
prof
it (£
m)
12
TSG Integration• TSG acquired in September 2017 for $17.0m (£13.2m) with additional contingent deferred
payment of $0.75m in December 2019• Funded from existing cash resources• Acquisition integration costs of £0.8m incurred to date• Contributed £4.9m revenue in 2017 (September to December)
• USA and UK account for 78% of revenue• Additional presence in Canada, Germany, France, Spain, Slovenia, Slovakia, Poland and Ireland. • Branch office in Romania has been closed post-acquisition
• USA Integration Programme• Separation of systems (incl payroll, benefits, IT) from vendor• Improving poor financial/operational controls and processes
• Europe Integration Programme• Creating integrated European strategy rather than historic autonomous units• Improving operational processes• Strengthening management team
13
1.00
1.10
1.20
1.30
1.40
1.50
1.60
Dec
-15
Jan-
16
Feb-
16
Mar
-16
Apr
-16
May
-16
Jun-
16
Jul-1
6
Aug
-16
Sep-
16
Oct
-16
Nov
-16
Dec
-16
Jan-
17
Feb-
17
Mar
-17
Apr
-17
May
-17
Jun-
17
Jul-1
7
Aug
-17
Sep-
17
Oct
-17
Nov
-17
Dec
-17
Jan-
18
30 June2017
30 December2017
• Foreign exchange benefit on Group revenue in 2017 compared to 2016 of £0.7 million• Average USD rate of 1.26 in H1-17 and 1.32 in H2-17 (H1-16: 1.44 and H2-16: 1.29)• Average Euro rate of 1.17 in H1-17 and 1.12 in H2-17 (H1-16: 1.30 and H2-16: 1.17)• While FX always uncertain, Board not anticipating benefit in 2018 and potentially negative
Currency Exchange RatesEx
chan
ge ra
te
30 June2016
31 December2016
GBP/USD
GBP/EUR
14
Net Funds + Freehold Property per Share• Strong asset base, comprising significant cash resources and freehold property assets• Decrease due to capital allocated to TSG acquisition• Property valuations to be undertaken in 2018
0
10
20
30
40
50
60
70
80
90
2010 2011 2012 2013 2014 2015 2016 2017
Net funds + freehold propertyper share (basic)
Net funds per share (basic)
Net
fund
s +
free
hold
pro
pert
y pe
r sha
re (p
ence
)
15
Corporation TaxEffective tax rate in 2017 is a tax charge of 22.2% (2016: 7.4%)
Tax charge in P&L of £0.9m in 2017 (2016: £0.2m)• R&D tax credit of £0.3m relating to 2017 (2016: R&D tax credit of £0.7m relating to 2015 & 2016) • One off tax cost in US of £120,000, Tax Cuts and Jobs Act (2016: £nil)• Significant adjustments largely ceased with R&D tax credit recognised in the year to which it relates.
Overall tax charge in line with substantively enacted corporation tax rates
Carried forward tax losses at 31 December 2017 of £11.4m (2016: £11.8m)• Includes £0.6m of trading tax losses (2016: £1.4m) which should partially reduce tax cash payments
• In 2017, cash inflow from R&D tax credits offset payments on account to give net cash outflow of £0.1m (2016: cash inflow of £0.6m)
• Other unrecognised tax losses of £10.8m (2016: £10.4m)• Will only be recognised if probable that losses can be utilised
16
Proposed PSP AmendmentsEquity based component of remuneration important to attract and retain key staff, particularly senior managers
PSP Option plan has been reviewed and amendments to be proposed at AGM:
• Exclude option grants related to TSG acquisition (400,000) from Plan limit• Increase annual limit to 1.5% of ISC (but not to exceed 600,000)• Remove “grace period” post-termination under normal circumstances• USA Addendum: Address anomaly to avoid negative tax consequence for USA
employee recipients• EEI Addendum
• Longer-term incentive with irregular larger awards (50,000 to 250,000). • All awards under EEI Addendum to be approved by shareholders (3 years)• Max aggregate award at any grant 1.2 million • Excludes any holder of 1.5% of ISC in shares or options• Vesting period: 5 years • Performance conditions based on share price appreciation in range 50% to 100%
17
Appendix
Annual Review of Capital Sources & Allocation
18
Capital Sources 2010-2017• Debt funding in 2010, 2013 and 2016
• Debt secured against Harston and Epsom freehold properties• Limited operating covenants due to asset security• 10 year term loan fixed at 3.5% using interest rate swap instrument to 2026
• Strong operating cash flow has been primary capital source• Extraordinary operating cash flow in 2016 included one-off items
0
3
6
9
12
15
18
21
2010 2011 2012 2013 2014 2015 2016 2017
£ m
illio
n
DebtEquity - Shares IssuedEquity - AcquisitionDisposal of investmentsOperating Cash Flow
“Equity – Shares Issued” comprises equity fund raising in 2010 and cash inflows from share option exercises thereafter
All balances exclude Client Registration Funds
19
• Major capital deployment related to TSG acquisition in 2017• Proposed dividend increase by 5%• Equity buy-backs undertaken when appropriate. None in 2017
Capital Allocation 2010-2017
0
2
4
6
8
10
12
14
16
18
2010 2011 2012 2013 2014 2015 2016 2017
£ m
illio
n
Dividend
Debt Repayment
Acquisition Consideration
Property, Plant & Equipment
Equity Buy-Back
Dividend is cash outflow timing, not period for which declared
20
• Capital resources deployed for acquisitions (2013, 2015, 2017)• Strong balance sheet maintained with cash resources for further investment/acquisition• Debt refinanced in 2016
Cash & Debt 2009-2017
-15
-10
-5
0
5
10
15
20
25
30
2009 2010 2011 2012 2013 2014 2015 2016 2017
£ m
illio
n
Gross Group Cash
Debt
Net Funds
Group Cash and Net Funds exclude cash held by TSG in respect of Client Registration Funds.
21
• Issued share capital has decreased by approx 5% since 2010• Acquisitions and investments funded primarily through operating cash flow• Share options and acquisition-related equity have been offset by share buy-backs
Equity Share Capital
0
10
20
30
40
50
60
mill
ion
shar
es
Outstanding ShareOptions
Issued Shares (ExclTreasury Shares) atyear end
34%
17%13%
5%
4%
26%
Chairman
Other Directors
Canaccord Genuity
Ruffer LLP
Miton
Charles Stanley
OtherShareholdings >3% as reported to Company as at 26 February 2018
Shares in issue (excluding treasury shares): 39.4m (2016: 39.3m)
22
Head officeHarston MillHarston, CambridgeCB22 7GGUK
Phone: +44 1223 [email protected]
www.sciencegroup.com
Head officeHarston MillHarston, CambridgeCB22 7GGUK
Phone: +44 1223 [email protected]
www.sciencegroup.com